451.26MMarket Cap-4629P/E (TTM)
9.780High9.220Low319.26KVolume9.300Open9.300Pre Close3.03MTurnover1.06%Turnover RatioLossP/E (Static)47.55MShares11.11052wk High3.12P/B287.20MFloat Cap1.33052wk Low--Dividend TTM30.26MShs Float60.516Historical High--Div YieldTTM6.02%Amplitude1.330Historical Low9.484Avg Price1Lot Size
Shattuck Labs Stock Forum
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
Update
🚀🚀🚀
Wait till lunch is over… 7 here we come
IN THE MONEY!!!!🤣😂🚀🚀🚀🖕🖕🤣😂💥💯
Wwweeeeeeeeee!!
No comment yet